Supplement for The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study (Journal of the American Academy of Dermatology, 2026)

Name: Supplement for The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study (Journal of the American Academy of Dermatology, 2026)
Creator: Carlos Wambier
Published: 2026-08-12T17:31:35.537Z
Keywords: Aging, Interleukin, Epigenetics, Psoriasis

Wambier, Carlos

doi:10.17632/69w24nt8kh.1

Supplement for The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study (Journal of the American Academy of Dermatology, 2026)

Published: 12 August 2026| Version 1 | DOI: 10.17632/69w24nt8kh.1

Contributor:

Description

Supplement to The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study, NCT05110313, PI Dr Carlos Wambier, MD, PhD, Rhode Island Hospital, Brown University Health. Figures S1-S6, and Supplementary Tables S1-S2, are within the PDF.

Supplement for The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study (Journal of the American Academy of Dermatology, 2026)

Description

Files

Institutions

Categories

Funders

Licence